A detailed history of E Fund Management Co., Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 7,561 shares of DNLI stock, worth $155,832. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,561
Previous 9,200 17.82%
Holding current value
$155,832
Previous $213,000 3.29%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$20.96 - $31.05 $34,353 - $50,890
-1,639 Reduced 17.82%
7,561 $220,000
Q2 2024

Aug 12, 2024

SELL
$14.96 - $23.22 $169,825 - $263,593
-11,352 Reduced 55.24%
9,200 $213,000
Q1 2024

May 13, 2024

BUY
$15.83 - $23.35 $51,637 - $76,167
3,262 Added 18.87%
20,552 $421,000
Q4 2023

Feb 06, 2024

BUY
$16.2 - $23.18 $89,245 - $127,698
5,509 Added 46.76%
17,290 $371,000
Q3 2023

Nov 13, 2023

SELL
$20.63 - $30.17 $32,595 - $47,668
-1,580 Reduced 11.83%
11,781 $243,000
Q2 2023

Aug 11, 2023

SELL
$23.37 - $32.96 $29,399 - $41,463
-1,258 Reduced 8.61%
13,361 $394,000
Q1 2023

May 11, 2023

SELL
$21.91 - $32.67 $5,302 - $7,906
-242 Reduced 1.63%
14,619 $337,000
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $15,951 - $20,589
607 Added 4.26%
14,861 $413,000
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $67,859 - $100,678
2,613 Added 22.45%
14,254 $437,000
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $58,756 - $99,024
2,814 Added 31.88%
11,641 $343,000
Q1 2022

May 12, 2022

BUY
$29.0 - $47.27 $193,836 - $315,952
6,684 Added 311.9%
8,827 $284,000
Q1 2021

May 12, 2021

BUY
$53.8 - $81.53 $115,293 - $174,718
2,143 New
2,143 $122,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.77B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.